Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00. Following the completion of the transaction, the chief executive officer owned 708,719 shares in the company, valued at approximately $53,947,690.28. The trade was a 2.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Helen Torley also recently made the following trade(s):

• On Thursday, February 5th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $78.64, for a total transaction of $786,400.00.
• On Monday, December 1st, Helen Torley sold 16,569 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $68.92, for a total transaction of $1,141,935.48.
• On Tuesday, November 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.13, for a total value of $1,382,600.00.

Halozyme Therapeutics Trading Up 0.6%

HALO traded up $0.49 during trading on Thursday, reaching $78.42. 2,481,744 shares of the company’s stock were exchanged, compared to its average volume of 1,709,236. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. Halozyme Therapeutics, Inc. has a one year low of $47.50 and a one year high of $79.50. The firm has a fifty day moving average price of $69.23 and a two-hundred day moving average price of $68.91. The stock has a market capitalization of $9.22 billion, a PE ratio of 16.51, a price-to-earnings-growth ratio of 0.32 and a beta of 0.97.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.09. The company had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. Halozyme Therapeutics’s revenue for the quarter was up 22.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.27 earnings per share. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on HALO. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday. Morgan Stanley reduced their price target on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research report on Monday, October 20th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Weiss Ratings lowered shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Finally, JPMorgan Chase & Co. boosted their price objective on Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a report on Monday, October 27th. Seven investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Hold” and an average target price of $78.80.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Root Financial Partners LLC purchased a new position in Halozyme Therapeutics during the third quarter worth about $25,000. Larson Financial Group LLC grew its holdings in shares of Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares in the last quarter. Richardson Financial Services Inc. grew its holdings in shares of Halozyme Therapeutics by 87.6% during the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 198 shares in the last quarter. Clearstead Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 107.7% during the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 265 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new stake in Halozyme Therapeutics during the second quarter worth about $32,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised a slate of quarterly and annual EPS estimates (notably Q1 2026 to $1.42 from $1.19, Q2 2026 to $1.80 from $1.49, Q3 2026 to $1.83 from $1.70, Q4 2026 to $2.38 from $1.84 and FY2026 to $7.43 from $6.22), signaling stronger expected profitability and supporting forward valuation. (summary of Zacks Research estimate updates)
• Positive Sentiment: An analyst raised Halozyme’s Q1 EPS forecast, which reinforces the near‑term beat narrative and likely contributed to buying interest. Q1 EPS Forecast for Halozyme Therapeutics Raised by Analyst
• Positive Sentiment: Zacks published a positive style/value write‑up describing HALO as a top long‑term value stock, which can attract value‑oriented and institutional buyers. Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
• Neutral Sentiment: Zacks trimmed its Q3 2027 estimate slightly (to $1.99 from $2.02); the change is minor relative to the larger upward revisions and unlikely to meaningfully reverse the positive sentiment unless further downgrades follow. (summary of Zacks Research estimate change)

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.